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E-mail address: xfzhou@uic.edu (X. Zhou).Deregulations of microRNA have been frequently observed in tongue squamous cell carcinoma
(TSCC), but their roles in tumorigenesis are not entirely clear. Here, we reported the up-regulation
of miR-24 in TSCC. MiR-24 up-regulation reduced the expression of RNA-binding protein dead end
1 (DND1). Knockdown of miR-24 led to enhanced expression of DND1. The direct targeting of
miR-24 to the DND1 mRNA was predicted bioinformatically and conﬁrmed by luciferase reporter
gene assays. Furthermore, the miR-24-mediated change in DND1 expression suppressed the expres-
sion of cyclin-dependent kinase inhibitor 1B (CDKN1B), and also led to enhanced proliferation and
reduced apoptosis in TSCC cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Oral squamous cell carcinoma (OSCC) is an undertreated and
understudied disease. According to the American Cancer Society
[1,2], while overall new cancer cases increased about 8% during
the past 5 years, the new cases for OSCC increased by about 21%,
and the new cases for OSCC of the tongue (TSCC, the most frequent
type of OSCC) increased by over 37% in the same period. More
strikingly, while the number of death associated with all cancers
decreased, the number of death associated with OSCC increased
by 4%, and the number of death associated with TSCC increased
by over 10% during the past 5 years. These statistics indicate a ma-
jor health problem, and point to the immediate need for a better
understanding of this disease. While attempts have been made to
identify genomic alterations that contribute to the initiation and
progression of TSCC, most efforts are focused on protein codingchemical Societies. Published by E
linois at Chicago, College of
60612, USA. Fax: +1 312 413genes. Our knowledge of genomic aberrations associated with
non-coding genes (e.g., microRNA) and their contributions to the
onset and propagation of TSCC is relatively limited.
MicroRNAs are a class of small non-coding RNAs of approxi-
mately 22 nucleotides in length that are endogenously expressed
in mammalian cells. They regulate the target gene expression at
the post-transcriptional level by repressing translation and/or
facilitating mRNA degradation. MicroRNAs are essential regulators
of a range of cellular processes including proliferation, differentia-
tion, apoptosis, survival, motility and morphogenesis. Several
microRNAs have been functionally classiﬁed as proto-oncogenes
or tumor suppressors [3], and are aberrantly expressed in different
cancer types, including OSCC [4–7].
Up-regulation of miR-24 has been observed in a number of can-
cers [8,9], including OSCC [10]. The up-regulation of miR-24 ap-
pears to be associated with the progression of OSCC [10]. Our
study conﬁrmed the up-regulation of miR-24 in TSCC, one of the
most common subtypes of OSCC. We further demonstrated that
miR-24 expresses its effects in part through targeting RNA-binding
protein DND1, which in turn post-transcriptionally regulates its
downstream genes, including cyclin-dependent kinase inhibitor
1B (CDKN1B).lsevier B.V. All rights reserved.
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2.1. Tumor procurement and RNA extraction
TSCC tissue samples and the adjacent normal tissues were ob-
tained from 6 TSCC patients. The demographics of the patients
were as follows: 4 male, 2 female; mean age of 52.3 years; there
were two T1 cases, three T2 cases and one T3 case. This study
was approved by Institutional Review Boards. Tissue samples were
obtained after the tumor resection and snap frozen. Specimens
containing more than 85% tumor cells on H&E pathological exam-
ination were selectively microdissected. The total RNA was isolated
using miRNeasy Mini kit (Qiagen), and quantiﬁed by the RiboGreen
RNA Quantitation Reagent (Molecular Probes).
2.2. Cell culture and transfection
The TSCC cell lines (UM1, UM2, Cal27, SCC4, SCC1, SCC2, SCC9,
SCC15, and SCC25) and immortalized NOK16B cell line used in this
study were maintained in DMEM/F12 supplemented with 10% FBS,
100 U/mL penicillin and 100 lg/mL streptomycin (GIBCO) at 37 C
in a humidiﬁed incubator containing 5% CO2. Primary normal hu-
man oral keratinocytes (NHOK) were prepared and cultured in
OKM medium (ScienCell Research Laboratory) as previously de-
scribed [11]. For functional analysis, the following reagents were
transfected into cells using DharmaFECT Transfection Reagent 1
as previously described [12]: miR-24 mimics and non-targeting
miRNA mimics (Dharmacon), locked nucleic acid knockdown
probe speciﬁc to miR-24 (anti-miR-24 LNA) and negative control
LNA (Exiqon), and gene speciﬁc siRNAs to DND1, CDKN1B and con-
trol non-targeting siRNA (On-TargetPlus SMARTpool, Dharmacon).
2.3. Quantitative RT-PCR analysis
The relative expression levels of miR-24 were determined using
GenoExplorer microRNA quantitative RT-PCR kit (GenoSensor
Crop.) as described previously [12]. The relative expression level
was computed using the 2ddCt analysis method [13], where U6
was used as an internal reference.
2.4. MicroRNA target prediction
The candidate targets of miR-24 were identiﬁed based on a con-
servative intersection of 3 common microRNA target prediction
tools: TargetScanHuman 5.1 [14], PicTar [15] and miRBase [16].
For our study, genes that were predicted by at least 2 of the meth-
ods were deﬁned as high conﬁdence candidate targets of miR-24.
2.5. Western blotting analysis
Western blots were performed as previously described [17]
using antibodies speciﬁc to DND1 (Sigma), CDKN2A (Cell Signal-
ing), CDKN1B (BD Biosciences) and beta-actin (Sigma). For semi-
quantiﬁcation, the western blot bands were quantiﬁed using a
ChemiDoc XRS System (Bio-Rad) equipped with Quantity One soft-
ware (version 4.6.3). The relative DND1 levels were expressed as
DND1/actin.
2.6. Dual luciferase reporter assay
A 65-bp fragment from the 30 untranslated region (30-UTR) of
DND1 (position 1442–1506, NM_194249) containing the predicted
miR-24 binding site was cloned into the Xba I site of the pGL3 ﬁre-
ﬂy luciferase reporter vector (Promega). The corresponding mutant
construct was created by mutating the seed region of the miR-24binding site. Using lipofectamine 2000 (Invitrogen), cells were
transfected with the reporter constructs containing either the tar-
geting sequence from the DND1 30-UTR (named pGL-DND1) or its
mutant (named pGL-DND1m). The pRL-TK vector (Promega) was
co-transfected as control for transfection efﬁciency. The luciferase
activities were then determined as previously described [17] using
a Lumat LB 9507 Luminometer (Berthold Technologies).
2.7. Proliferation and apoptosis assay
Cell proliferation was measured by MTT assay as previously de-
scribed [18], with minor modiﬁcation. In brief, 48 h post transfec-
tion, medium in each well was replaced by 100 ll of fresh serum-
free mediumwith 0.5 g/L MTT. After incubation at 37 C for 4 h, the
MTT medium was aspirated out and 50 ll of DMSO was added to
each well. After incubation at 37 C for another 10 min, the absor-
bance value of each well was measured using a plate reader at a
wavelength of 540 nm. The apoptosis was measured using the An-
nexin V-FITC Apoptosis Detection Kit (Invitrogen) and measured
with a ﬂow cytometer (FACScalibur, Becton–Dickinson) as previ-
ously described [12].
2.8. Statistical analysis
Data are presented as means ± S.D. The differences between
groups were determined by Student’s t-test (two-tailed). Differ-
ences were declared signiﬁcant at P < 0.05 level. Correlations were
assessed using Pearson’s correlation coefﬁcient.
3. Results
3.1. Up-regulation of miR-24 in TSCC
As shown in Fig. 1A, enhanced miR-24 levels were observed in
TSCC tissue samples as compared to the normal tissue samples
from the same patients. Enhanced miR-24 levels were also ob-
served in 7 out of the 8 TSCC cell lines as compared to the non-
tumorgenic cells (NOK16B and NHOK) (Fig. 1B).
3.2. Bioinformatics analysis of miR-24 targets
To further explore the functional roles of miR-24 in TSCC, a bio-
informatics-analysis was carried out to identify the potential tar-
gets for miR-24 as described in Section 2. A total of 102
candidate targets for miR-24 were identiﬁed (predicted by at least
2 methods, Supplementary Table 1). Among those predicted tar-
gets, the dead end 1 (DND1) gene encodes for a RNA-binding pro-
tein that is involved in nucleic acid editing [19] and regulation of
mRNA stability [20]. The reverse target prediction analysis indi-
cated that there are potentially 4 microRNAs that target DND1,
including miR-24, miR-370, miR-634, and miR-889 (predicted by
at least 2 methods, Supplementary Table 2). While up-regulation
of miR-24 has been shown in TSCC, the levels of miR-634 and
miR-889 were undetectable in our samples, and miR-370 was
not differentially expressed in TSCC (data not shown). The bioinfor-
matics analyses led us to investigate the functional relevance of the
miR-24 effect on DND1 in TSCC cells.
3.3. DND1 is a direct target of miR-24
As shown in Fig. 2, the levels of miR-24 and DND1 were inver-
sely correlated in TSCC cell lines (Pearson’s correlation coefﬁ-
cient = 0.89, P = 0.003, Supplementary Fig. 1).
Based on the bioinformatics analysis, a highly-conserved miR-
24 targeting sequence was identiﬁed in the 30-untranslated region
of DND1mRNA (Fig. 3A and B). To conﬁrm that miR-24 directly tar-
Fig. 1. Enhanced miR-24 level in TSCC. The qRT-PCR was performed to assess the miR-24 level in: (A) TSCC and their normal control tissue samples, and (B) a panel of TSCC
cell lines, and an immortalized non-tumorgenic cell lines (NOK16B), and normal oral keratinocyte cell culture (NHOK). Statistically signiﬁcant increases in miR-24 levels were
observed for the paired tissue samples (P < 0.05). For the TSCC cell lines tested, up-regulation in miR-24 levels were observed in 7 of the 8 TSCC cell lines when compared to
NHOK or NOK16B (P < 0.05).
Fig. 2. Correlation of miR-24 and DND1 levels in TSCC. The levels of miR-24 and
DND1 were determined in TSCC cell lines based on quantitative RT-PCR and
Western blot, respectively. A reverse correlation between miR-24 and DND1 levels
was observed (Pearson’s correlation coefﬁcient = 0.89, P = 0.003).
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using the construct in which this targeting site was cloned into the
30-UTR of the reporter gene (pGL-DND1). As illustrated in Fig. 3C,
when cells were treated with anti-miR-24 LNA, the luciferase
activities were signiﬁcantly enhanced as compared to the cells
treated with scrambled LNA. When cells were transfected with
miR-24 mimic, the luciferase activities were signiﬁcantly reduced
as compared to the cells transfected with negative control
(Fig. 3D). When the seed region of the targeting site was mutated
(pGL-DND1m), the miR-24 effects on the luciferase activity were
abolished. Furthermore, as shown byWestern blot (Fig. 3E), knock-
down of miR-24 using anti-miR-24 LNA increased the protein level
of DND1 in UM2 cells. Similarly, CDKN2A, a known target of miR-
24 [21], was also up-regulated by anti-miR-24 LNA treatment. In
contrast, ectopic transfection of miR-24 reduced the protein levels
of both DND1 and CDKN2A in UM2 cells (Fig. 3F). Similar results
were observed in UM1 cells and HeLa cells (data not shown).
3.4. MiR-24-mediated down-regulation of DND1 reduces the CDKN1B
expression, and regulates proliferation and apoptosis in TSCC cells
It has been shown previously that the expression of cyclin-
dependent kinase inhibitor 1B (CDKN1B) is up-regulated by DND1at the post-transcriptional level [20]. Here, we demonstrated that
knock-down of DND1 by siRNA led to reduced expression of
CDKN1B in TSCC cells (Fig. 4A). This DND1 knockdown-mediated
down-regulation of CDKN1B was accompanied by enhanced prolif-
eration (Fig. 4E) and reduced apoptosis (Fig. 4I). Similar effects on
proliferation and apoptosis were also observed when cells were
treated with siRNA speciﬁc to CDKN1B (Fig. 4F and J). The miR-24-
mediated down-regulation of DND1 also resulted in reduced
CDKN1B expression (Fig. 4C), which was accompanied by enhanced
proliferation (Fig. 4G) and reduced apoptosis (Fig. 4K). In contrast,
knockdown of miR-24 by anti-miR24 LNA treatment resulted in en-
hanced DND1 expression, which led to enhanced CDKN1B expres-
sion (Fig. 4D). This was associated with a concomitant reduction
in cell proliferation (Fig. 4H) and increased apoptosis (Fig. 4L).
4. Discussion
In this study, we reported the up-regulation of miR-24 in TSCC.
This ﬁnding is in agreement with the recent observation that miR-
24 is up-regulated in OSCC and contributes to the growth of OSCC
cells in vitro [10]. In addition, up-regulation of miR-24 has also
been observed in gastric and cervical cancers [8,9]. However, its
role in tumorigenesis is not entirely clear.
To understand the role(s) of microRNA in complex systems (i.e.,
TSCC), it is important to identify the functional modules involved
in complex interactions between microRNA and their targets
(e.g., mRNA). In our study, by combining 3 commonly used microR-
NA target prediction methods (PicTar, TargetScanand and miRan-
da), a number of important candidate targets for miR-24 were
predicted. Among these potential targets, DND1 is the most
intriguing target, as DND1 has been shown to modulate microRNA
activity by binding to the microRNA targeting sequences on the 30-
UTR of the targeted mRNAs [20]. Therefore, DND1 post-transcrip-
tionally regulates gene expression by inhibiting the microRNA ac-
cess to the target mRNA. Previous studies demonstrated that DND1
is essential for the motility and survival of germ cells in zebraﬁsh
[19], and disruption of DND1 gene can induce testicular germ cell
tumors in mice [22].
Our functional analysis conﬁrmed that DND1 is a direct target of
miR-24. Furthermore, the miR-24 mediated regulation of DND1
expression also inferences the expression of CDKN1B, one of the
known DND1 regulating genes [20]. Knockdown of DND1 by siRNA
or ectopic transfection of miR-24 led to the reduced expression of
Fig. 3. MiR-24 direct targeting DND1 mRNA. (A) The predicted miR-24 targeting sequence located in the 30-untranslated region (30-UTR) of DND1 mRNA. The seed region is
highlighted in yellow. (B) The alignment of the miR-24 targeting sequences located in the 30-UTR of the DND1 genes from 23 organisms. The evolutionarily conserved
nucleotides are indicated with capital letters in the sequence shown on the bottom. Dual luciferase reporter assays were performed as described in Section 2 section on cells
transfected with constructs containing the predicted targeting sequence (pGL-DND1) or mutated targeting sequence (pGL-DND1m) cloned into the 30-UTR of the reporter
gene, and treated with anti-miR-24 LNA or scramble LNA (C), or treated with miR-24 mimic or control mimic (D). *Indicates P < 0.05. Western blot analyses were performed to
examine the effects of miR-24 on DND1 expression in UM2 cells that were treated with anti-miR-24 LNA or scramble LNA (E), or on cells that were treated with miR-24 mimic
or control mimic (F). The expression of CDKN2A, a known target of miR-24 [21], was also examined in these cells. Data represents at least three independent experiments
with similar results.
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DND1 expression led to enhanced CDKN1B expression.
The miR-24 effect on in-direct target genes (e.g., CDKN1B)
through down-regulating the RNA-binding protein DND1 is
intriguing (Fig. 5). It is worth knowing that CDKN1B is directly tar-
geted by miR-221/222. We have previously conﬁrmed that miR-
222 down-regulates the CDKN1B expression in TSCC cells [17].
Interestingly, the targeting site for miR-221/222 on the 30-UTR of
the CDKN1B mRNA overlaps with the DND1 binding site [20]. This
overlap provided an additional in-direct regulatory mechanism
wherein DND1 can inhibit microRNA access to the target mRNA,
and therefore regulates the miR-221/222 mediated down-regula-
tion of CDKN1B expression. With our newly gained knowledge of
miR-24 mediated down-regulation of DND1, we expected that
miR-24 and miR-221/222 would have a synergistic effect on
CDKN1B expression. However, while both miR-24 and miR-221/
222 altered the CDKN1B expression independently, no synergistic
effect was observed on CDKN1B expression when cells were con-
currently treated with miR-24 and miR-221/222 (data not shown).
It appears that the miR-221/222 mediated regulation of CDKN1B
gene expression is not interacting with the miR-24/DND1 pathway.
Alternatively, it is possible that the potential synergistic effect of
miR-24 and miR-221/222 on CDKN1B expression may involve
additional unknown molecular regulator(s). It is worth knowing
that DND1 prohibits the accessibility of several other microRNAs
to their target mRNAs [20], and appears to be a general biological
function of DND1. Similarly, HuR, another RNA-binding protein,
has also been shown to inhibit miR-122-mediated repression ofgene expression by binding to the 30-UTR of the target gene mRNA
[23]. Together, these observations indicate that microRNAs regu-
late target gene expression through different mechanisms, includ-
ing direct cis-regulation (miR-221/222 direct targeting CDKN1B)
and in-direct trans-regulation (miR-24 in-direct controlling of
CDKN1B gene expression by targeting RNA-binding protein DND1).
Our bioinformatics analysis also predicted that CDKN1B is di-
rectly targeted by miR-24. A highly conserved binding site for
miR-24 was predicted in the 30-UTR of the CDKN1B mRNA. How-
ever, our luciferase reporter gene assay failed to conﬁrm a func-
tional interaction of miR-24 and this binding site (data not
shown). Therefore, it appears that CDKN1B is not directly targeted
by miR-24 in our system. Nevertheless, it remains possible that
miR-24 may directly target CDKN1B in other cell types or different
biological systems. Our data also conﬁrmed the previous observa-
tion that miR-24 suppress the expression of CDKN2A [21], another
important cell cycle regulator. Taken together, these results sug-
gest that miR-24 is a putative oncogenic microRNA in TSCC. This
is further supported by recent observation that enhanced miR-24
level is associated with the progression of OSCC [10].
In summary, miR-24 is a multi-functional molecule regulator
that regulates a variety of biological processes. One of its major
roles in TSCC is regulating cell proliferation and apoptosis by tar-
geting inhibitors of cyclin-dependent kinases (e.g., CDKN1B and
CDKN2A). Furthermore, the results from the present study suggest
an intriguing mechanism for miR-24 to express its effects through
targeting DND1, which in turn regulates a group of downstream
genes at post-transcriptional levels.
Fig. 4. The effect of miR-24 on DND1 and CDKN1B expression and cell growth. The UM2 cells were treated with DND1 speciﬁc siRNA or control siRNA (A, E and I), CDKN1B
speciﬁc siRNA or control siRNA (B, F and J), miR-24 mimic or control mimic (C, G and K), and anti-miR-24 LNA or scramble LNA (D, H and L). Western blot were performed on
these cells to examine the expression of DND1 and CDKN1B genes (A–D). Proliferation (E–H) and apoptosis (I–L) were also measured in these cells. Data represents at least
three independent experiments with similar results. *Indicates P < 0.05, and #indicates P < 0.1.
Fig. 5. Potential mechanisms utilized by miR-24 to regulate cell proliferation in
TSCC.
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